Linguamatics and the US FDA
August 24, 2012
Linguamatics recently announced that the FDA’s Center for Drug Evaluation and research (CDER) is set to use their I2E platform, which is the company’s interactive data mining and extraction software across CDER’s laboratory research relating to drug safety.
The write-up “Linguamatics’ I2E Text Mining Platform Chosen by FDA” provides more details about why the text mining company was selected by the CDER:
“I2E’s NLP-based querying capabilities, coupled with its scalability and flexibility, mean it is ideally suited to answering many challenging, high value questions in life sciences and healthcare by unlocking knowledge buried in the scientific literature and other textual information. Rather than just retrieving documents, I2E can rapidly identify, extract, synthesize and analyze specific, relevant facts and relationships, such as those between genes and diseases or compounds and side effects. Customers include nine of the top ten global pharmaceutical companies.”
What’s great about the I2E platform is that unlike other text mining systems, I2E provides businesses with full control over what information is to be extracted, what query definitions are, and the kind of output. With it, users can obtain information in a short period of time even from large documents.
Again, another company from the science sector has opted to use Linguamatics’ I2E platform. CDER joins Pfizer, Selventa, AstraZeneca, and others from the company’s roster of prestigious clients. Linguamatics has truly evolved from being a small player to being the industry leader in NLP-based text mining within just a few years. We’re excited to see what the company will become two to three years from now.
Lauren Llamanzares, August 24, 2012